Opdivo plus chemotherapy improved median OS to 14.4 months versus 11.1 months in patients with PD-L1 CPS ≥5. The 5-year OS rates were 16% for Opdivo plus chemotherapy and 6% for chemotherapy alone in ...
A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial). A quality-adjusted time without symptoms ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results